共 36 条
[1]
Faggiano A(2012)Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study J Endocrinol Invest 35 817-823
[2]
Ferolla P(2016)ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors Neuroendocrinology 103 153-171
[3]
Grimaldi F(2012)Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1) J Clin Endocrinol Metab 97 2990-3011
[4]
Falconi M(2006)Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas Ann Surg 243 265-272
[5]
Eriksson B(2017)Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours Clin Endocrinol (Oxf) 86 199-206
[6]
Kaltsas G(2019)Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters The Journal of Clinical Endocrinology & Metabolism 105 78-84
[7]
Thakker RV(2009)Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 4656-4663
[8]
Newey PJ(2014)Lanreotide in metastatic enteropancreatic neuroendocrine tumors N Engl J Med 371 224-233
[9]
Walls GV(2016)ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site Neuroendocrinology 103 172-185
[10]
Triponez F(undefined)undefined undefined undefined undefined-undefined